BioRestorative Therapies, Inc. (BRTX)
NASDAQ: BRTX · Real-Time Price · USD
1.500
0.00 (0.00%)
Aug 13, 2025, 4:00 PM - Market open
BioRestorative Therapies Employees
BioRestorative Therapies had 11 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
11
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$35,545
Profits / Employee
-$1,099,630
Market Cap
11.97M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BRTX News
- 1 day ago - BioRestorative Therapies, Inc. (BRTX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - BioRestorative Therapies to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025 - GlobeNewsWire
- 2 months ago - BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Compelling BRTX-100 Clinical Data, Leadership Enhancements and Strategic updates - GlobeNewsWire
- 2 months ago - BioRestorative Announces Share Repurchase Program - GlobeNewsWire
- 2 months ago - BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease - GlobeNewsWire
- 2 months ago - BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025 - GlobeNewsWire
- 3 months ago - BioRestorative Therapies, Inc. (BRTX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data - GlobeNewsWire